HSBC has initiated coverage of Waters with a Buy rating and a $460 price target. The bank believes the pending acquisition of Biosciences and Diagnostic Solutions could drive growth through synergies. HSBC anticipates mid-teens earnings growth supported by equipment replacement cycles and revenue synergies. The deal, valued at $17.5 billion, is expected to close by the end of Q1 2026.

This positive outlook stems from the potential for a more diversified life sciences and diagnostics group. HSBC expects the expanded footprint to support strong growth and margin performance. However, HSBC acknowledges investor concerns about the deal's price and uncertainties in China. Despite these risks, the bank sees strategic benefits being underestimated by the market.

HSCB's forecasts are based on Waters on a standalone basis and sees key near-term catalysts. Completion of the deal and Waters' fiscal 2025 results on February 12th are critical. The $460 price target is derived from a 24x pro forma 2028 earnings multiple. The acquisition could position Waters for significant market share gains.

Waters’ pending acquisition of BD's business could be a turning point. The deal will likely increase the company's exposure to the growing diagnostics market. Investors will be watching for the finalization of the deal and how the combined entity performs. The company's future hinges on its ability to integrate the new assets and capitalize on anticipated synergies.